{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:02:37Z","timestamp":1784581357418,"version":"3.55.0"},"reference-count":74,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Helmholtz Initiative","award":["InterLabs-0031"],"award-info":[{"award-number":["InterLabs-0031"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Prostate specific membrane antigen (PSMA) is an excellent target for imaging and treatment of prostate carcinoma (PCa). Unfortunately, not all PCa cells express PSMA. Therefore, alternative theranostic targets are required. The membrane protein prostate stem cell antigen (PSCA) is highly overexpressed in most primary prostate carcinoma (PCa) cells and in metastatic and hormone refractory tumor cells. Moreover, PSCA expression positively correlates with tumor progression. Therefore, it represents a potential alternative theranostic target suitable for imaging and\/or radioimmunotherapy. In order to support this working hypothesis, we conjugated our previously described anti-PSCA monoclonal antibody (mAb) 7F5 with the bifunctional chelator CHX-A\u2033-DTPA and subsequently radiolabeled it with the theranostic radionuclide 177Lu. The resulting radiolabeled mAb ([177Lu]Lu-CHX-A\u2033-DTPA-7F5) was characterized both in vitro and in vivo. It showed a high radiochemical purity (&gt;95%) and stability. The labelling did not affect its binding capability. Biodistribution studies showed a high specific tumor uptake compared to most non-targeted tissues in mice bearing PSCA-positive tumors. Accordingly, SPECT\/CT images revealed a high tumor-to-background ratios from 16 h to 7 days after administration of [177Lu]Lu-CHX-A\u2033-DTPA-7F5. Consequently, [177Lu]Lu-CHX-A\u2033-DTPA-7F5 represents a promising candidate for imaging and in the future also for radioimmunotherapy.<\/jats:p>","DOI":"10.3390\/ijms24119420","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T07:54:16Z","timestamp":1685346856000},"page":"9420","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Preclinical Characterization of the 177Lu-Labeled Prostate Stem Cell Antigen (PSCA)-Specific Monoclonal Antibody 7F5"],"prefix":"10.3390","volume":"24","author":[{"given":"Franziska","family":"Striese","sequence":"first","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"},{"name":"School of Science, Faculty of Chemistry and Food Chemistry, Technical University Dresden, 01062 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0646-5808","authenticated-orcid":false,"given":"Christin","family":"Neuber","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Gr\u00e4\u00dfel","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"},{"name":"School of Science, Faculty of Chemistry and Food Chemistry, Technical University Dresden, 01062 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-5052","authenticated-orcid":false,"given":"Claudia","family":"Arndt","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6104-6676","authenticated-orcid":false,"given":"Martin","family":"Ullrich","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Steinbach","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"},{"name":"School of Science, Faculty of Chemistry and Food Chemistry, Technical University Dresden, 01062 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1610-1493","authenticated-orcid":false,"given":"Jens","family":"Pietzsch","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"},{"name":"School of Science, Faculty of Chemistry and Food Chemistry, Technical University Dresden, 01062 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-4286","authenticated-orcid":false,"given":"Ralf","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"},{"name":"Institute of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Pietzsch","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Sihver","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Frenz","sequence":"additional","affiliation":[{"name":"Faculty of Informatik and Wirtschaftsinformatik, Provadis School of International Management and Technology AG, 65926 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Feldmann","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-5755","authenticated-orcid":false,"given":"Michael P.","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany"},{"name":"National Center for Tumor Diseases (UCC\/NCT), Partner Site Dresden, 01307 Dresden, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3389\/fonc.2019.00884","article-title":"Past, current, and future of immunotherapies for prostate cancer","volume":"9","author":"Boettcher","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1158\/1078-0432.CCR-06-0067","article-title":"Mechanisms underlying the development of androgen-independent prostate cancer","volume":"12","author":"Pienta","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.semnuclmed.2010.08.005","article-title":"PET\/CT imaging and radioimmunotherapy of prostate cancer","volume":"41","author":"Bouchelouche","year":"2011","journal-title":"Semin. Nucl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3892\/ol.2017.5911","article-title":"The context of prostate cancer genomics in personalized medicine","volume":"13","author":"Liu","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1148\/radiol.2431030580","article-title":"Imaging prostate cancer: A multidisciplinary perspective","volume":"243","author":"Hricak","year":"2007","journal-title":"Radiology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1148\/rg.2016150059","article-title":"Molecular imaging of prostate cancer","volume":"36","author":"Wibmer","year":"2016","journal-title":"Radiographics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"66112","DOI":"10.18632\/oncotarget.19805","article-title":"177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer","volume":"8","author":"Kiljunen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer","volume":"41","author":"Rahbar","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00259-017-3751-z","article-title":"177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer","volume":"44","author":"Grubert","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17588359231157632","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: Current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Malcher","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","article-title":"Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: A new PET tracer for imaging of prostate cancer","volume":"7","author":"Eder","year":"2014","journal-title":"Pharmaceuticals"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid \u2076\u2078Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.18632\/oncotarget.27239","article-title":"The positivity rate of 68Gallium-PSMA-11 ligand PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer","volume":"10","author":"Hoffmann","year":"2019","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","article-title":"Intraindividual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study","volume":"59","author":"Giesel","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1659095","DOI":"10.1080\/2162402X.2019.1659095","article-title":"A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR","volume":"8","author":"Arndt","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jlcr.3727","article-title":"Theranostic CAR T cell targeting: A brief review","volume":"62","author":"Arndt","year":"2019","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00262-019-02399-5","article-title":"Conventional CARs versus modular CARs","volume":"68","author":"Feldmann","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","article-title":"The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells","volume":"211","author":"Bachmann","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/RLU.0000000000001480","article-title":"Excellent response to 177Lu-PSMA-617 radioligand therapy in a patient with advanced metastatic castration resistant prostate cancer evaluated by 68Ga-PSMA PET\/CT","volume":"42","author":"Roll","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.117.204677","article-title":"(68)Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging","volume":"59","author":"Rischpler","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.18383\/j.tom.2015.00169","article-title":"Uptake of (18)F-DCFPyL in Paget\u2019s disease of bone, an important potential pitfall in clinical interpretation of PSMA PET Studies","volume":"1","author":"Rowe","year":"2015","journal-title":"Tomography"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/1754-9485.12357","article-title":"Gallium-68 PSMA uptake in adrenal adenoma","volume":"60","author":"Law","year":"2016","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/RLU.0000000000001084","article-title":"Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET\/CT","volume":"41","author":"Kanthan","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","article-title":"Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis","volume":"15","author":"Mannweiler","year":"2009","journal-title":"Pathol. Oncol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.18383\/j.tom.2018.00021","article-title":"Pitfalls in gallium-68 PSMA PET\/CT interpretation\u2014A pictorial review","volume":"4","author":"Shetty","year":"2018","journal-title":"Tomography"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2967\/jnumed.118.207993","article-title":"PSMA-targeted radionuclide therapy and salivary gland toxicity: Why does it matter?","volume":"59","author":"Taieb","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_29","first-page":"3081","article-title":"Prostate stem cell antigen is expressed in normal and malignant human brain tissues","volume":"15","author":"Ono","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"54592","DOI":"10.18632\/oncotarget.17523","article-title":"Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2\/neu overexpression","volume":"8","author":"Link","year":"2017","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2005.05.021","article-title":"Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostate tissues","volume":"236","author":"Cunha","year":"2006","journal-title":"Cancer Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","article-title":"Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer","volume":"19","author":"Gu","year":"2000","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/cancers4010193","article-title":"Tumor-associated antigens for specific immunotherapy of prostate cancer","volume":"4","author":"Kiessling","year":"2012","journal-title":"Cancers"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/01.ju.0000109982.60619.93","article-title":"Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer","volume":"171","author":"Han","year":"2004","journal-title":"J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-04-1842","article-title":"Prostate stem cell antigen is overexpressed in prostate cancer metastases","volume":"11","author":"Lam","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2013.01.002","article-title":"Retargeting of regulatory T cells to surface-inducible autoantigen La\/SS-B","volume":"42","author":"Koristka","year":"2013","journal-title":"J. Autoimmun."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cartellieri, M., Koristka, S., Arndt, C., Feldmann, A., Stamova, S., von Bonin, M., Topfer, K., Kruger, T., Geib, M., and Michalk, I. (2014). A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093745"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"31368","DOI":"10.18632\/oncotarget.15572","article-title":"Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR\u201d","volume":"8","author":"Feldmann","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.4049\/jimmunol.1200341","article-title":"Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells","volume":"189","author":"Feldmann","year":"2012","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/pros.20608","article-title":"Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells","volume":"67","author":"Morgenroth","year":"2007","journal-title":"Prostate"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/pros.21315","article-title":"Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats","volume":"71","author":"Feldmann","year":"2011","journal-title":"Prostate"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/pros.22850","article-title":"Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system","volume":"74","author":"Arndt","year":"2014","journal-title":"Prostate"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaut.2018.02.006","article-title":"Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology","volume":"90","author":"Koristka","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1785608","DOI":"10.1080\/2162402X.2020.1785608","article-title":"Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy","volume":"9","author":"Feldmann","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"25597","DOI":"10.18632\/oncotarget.25390","article-title":"From mono- to bivalent: Improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro und in vivo","volume":"9","author":"Albert","year":"2018","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","article-title":"Determination of the Immunoreactive Fraction of Radiolabeled Monoclonal-Antibodies by Linear Extrapolation to Binding at Infinite Antigen Excess","volume":"72","author":"Lindmo","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ren, J., Wang, F., Wei, G., Yang, Y., Liu, Y., Wei, M., Huan, Y., Larson, A.C., and Zhang, Z. (2012). MRl of prostate cancer antigen expression for diagnosis and immunotherapy. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038350"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1158\/0008-5472.CAN-05-2086","article-title":"Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism","volume":"65","author":"Gu","year":"2005","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1073\/pnas.051624698","article-title":"Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts","volume":"98","author":"Saffran","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1874471008666150312155959","article-title":"Evolving important role of lutetium-177 for therapeutic nuclear medicine","volume":"8","author":"Pillai","year":"2015","journal-title":"Curr. Radiopharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1874471008666150313104212","article-title":"Radiation dosimetry aspects of 117Lu","volume":"8","author":"Lassmann","year":"2015","journal-title":"Curr. Radiopharm."},{"key":"ref_52","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"Bardies","year":"1995","journal-title":"J. Nucl. Med."},{"key":"ref_53","first-page":"297","article-title":"Radioimmunotherapy of prostate cancer","volume":"48","year":"2004","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrd1413","article-title":"Antibody-targeted radiation cancer therapy","volume":"3","author":"Milenic","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_55","unstructured":"Speer, T.W. (2011). Targeted Radionuclide Therapy, Lippincott Williams & Wilkins, a Wolters Kluwer Business."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Aktolun, C., and Goldsmith, S.J. (2013). Nuclear Medicine Therpay: Principles and Clinical Applications, Springer.","DOI":"10.1007\/978-1-4614-4021-5"},{"key":"ref_57","first-page":"904","article-title":"Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy","volume":"52","author":"Kosmas","year":"1992","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jlcr.3413","article-title":"(90) Y\/(177) Lu-labelled Cetuximab immunoconjugates: Radiochemistry optimization to clinical dose formulation","volume":"59","author":"Chakravarty","year":"2016","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00259-002-1054-4","article-title":"The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity","volume":"30","author":"Breeman","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.nucmedbio.2006.09.003","article-title":"In vitro and in vivo characterization of 177Lu-huA33: A radioimmunoconjugate against colorectal cancer","volume":"33","author":"Almqvist","year":"2006","journal-title":"Nucl. Med. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1524\/ract.2007.95.6.351","article-title":"177Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems","volume":"95","author":"Fani","year":"2007","journal-title":"Radiochim. Acta"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jlcr.3707","article-title":"Preparation of (177) Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: Comparison of DOTA and CHX-A\u2019\u2019-DTPA as bifunctional chelators","volume":"62","author":"Pandey","year":"2019","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.1038\/s41598-018-27355-8","article-title":"Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer","volume":"8","author":"Dho","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00259-005-1902-0","article-title":"[(177)Lu]pertuzumab: Experimental studies on targeting of HER-2 positive tumour cells","volume":"32","author":"Persson","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.nucmedbio.2010.04.020","article-title":"Anti-EGFRvIII monoclonal antibody armed with 177Lu: In vivo comparison of macrocyclic and acyclic ligands","volume":"37","author":"Hens","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"ref_66","first-page":"240","article-title":"Synthesis and preclinical evaluation of 177Lu-CHX-A\u2019\u2019-DTPA-rituximab as aradioimmunotherapeutic agent for Non-Hodgkin\u2019s Lymphoma","volume":"30","author":"Kameswaran","year":"2015","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_67","first-page":"1191","article-title":"A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier","volume":"31","author":"Fujimori","year":"1990","journal-title":"J. Nucl. Med."},{"key":"ref_68","first-page":"155","article-title":"Affinity and avidity in antibody-based tumor targeting","volume":"24","author":"Rudnick","year":"2009","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1083\/jcb.71.1.159","article-title":"125I-Labeled human epidermal growth factor","volume":"71","author":"Carpenter","year":"1976","journal-title":"J. Cell. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1087057115613270","article-title":"High-throughput screening for internalizing antibodies by homogeneous fluorescence imaging of a pH-activated probe","volume":"21","author":"Riedl","year":"2016","journal-title":"J. Biomol. Screen"},{"key":"ref_71","first-page":"2546","article-title":"Prostate stem cell antigen as therapy target: Tissue expression and in vivo efficacy of an immunoconjugate","volume":"62","author":"Ross","year":"2002","journal-title":"Caner Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2967\/jnumed.117.189944","article-title":"Pretargeted imaging and therapy","volume":"58","author":"Altai","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1039\/C5CS00784D","article-title":"New insights into the pretargeting approach to image and treat tumours","volume":"45","author":"Patra","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8774","DOI":"10.1021\/acs.jmedchem.8b00932","article-title":"Improved conjugation, 64-Cu radiolabeling, in vivo stability, and imaging using nonprotected bifunctional macrocyclic ligands: Bis(phosphinate) cyclam (BPC) chelators","volume":"61","author":"David","year":"2018","journal-title":"J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9420\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:44:09Z","timestamp":1760125449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":74,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24119420"],"URL":"https:\/\/doi.org\/10.3390\/ijms24119420","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]}}}